UBS Maintains Buy on Assembly Biosciences, Lowers Price Target to $48
Benzinga Newsdesk 6 hours ago
Analyst RatingsNewsPrice Target
UBS analyst Ashwani Verma maintains Assembly Biosciences (NASDAQ:ASMB) with a Buy and lowers the price target from $52 to $48.
UBS analyst Ashwani Verma maintains Assembly Biosciences (NASDAQ:ASMB) with a Buy and lowers the price target from $52 to $48.